Medacta Group SA
SIX:MOVE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
106.4
134
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Medacta Group SA
Medacta Group SA
Cash & Cash Equivalents
Medacta Group SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medacta Group SA
SIX:MOVE
|
Cash & Cash Equivalents
€20.8m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Metall Zug AG
SIX:METN
|
Cash & Cash Equivalents
CHf17.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Sonova Holding AG
SIX:SOON
|
Cash & Cash Equivalents
CHf266.3m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
|
|
Straumann Holding AG
SIX:STMN
|
Cash & Cash Equivalents
CHf410.3m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Medmix Ltd
SIX:MEDX
|
Cash & Cash Equivalents
CHf112.1m
|
CAGR 3-Years
96%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Medacta Group SA
Glance View
Medacta Group SA, hailing from the picturesque setting of Castel San Pietro, Switzerland, stands as a prominent player in the global medical technology arena. Founded in 1999, the company has capitalized on a family-driven passion for innovation and precision in the orthopedic industry. Guided by its roots, Medacta designs and supplies orthopedic implants and surgical instruments, with a staunch focus on products for joint replacement, spine surgery, and sports medicine. But beyond mere manufacturing, Medacta combines cutting-edge research with in-depth medical training programs, ensuring that healthcare professionals are not only equipped with superior products but also with the necessary skills to optimize patient outcomes. The company’s MyPractice Development Plan exemplifies this by pairing technical support with educational efforts, fostering both confidence and competence among its professional clients. Medacta’s business model is a synthesis of product sales and continuous practitioner engagement. Revenue streams primarily flow from the direct sale of their extensive product portfolio, including implants and surgical instruments, to hospitals and surgical centers. However, Medacta's strategy extends its competitive advantage by nurturing strong relationships with medical professionals through training and support initiatives. This symbiotic approach ensures a feedback loop that not only tailors their offerings to the evolving needs of the marketplace but also solidifies client loyalty. Their innovative and educational initiatives secure a unique position in the market, allowing Medacta to maintain a balance of economic success and industry leadership by focusing on quality, innovation, and education.
See Also
What is Medacta Group SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
20.8m
EUR
Based on the financial report for Dec 31, 2023, Medacta Group SA's Cash & Cash Equivalents amounts to 20.8m EUR.
What is Medacta Group SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-9%
Over the last year, the Cash & Cash Equivalents growth was -36%. The average annual Cash & Cash Equivalents growth rates for Medacta Group SA have been -24% over the past three years , -9% over the past five years .
You don't have any saved screeners yet